JSSH(SZ:000518)2022-08-19 16:00Financial Performance - The company's operating revenue for the first half of 2022 was ¥118,397,374.09, a decrease of 20.94% compared to ¥149,748,660.35 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was -¥32,927,209.66, representing a decline of 19.00% from -¥27,669,307.65 in the previous year[19]. - The company reported a basic earnings per share of -¥0.0320, a decrease of 18.96% from -¥0.0269 in the previous year[19]. - The weighted average return on net assets was -5.58%, a decline of 1.17% from -4.41% in the previous year[19]. - The company reported a net profit of 112,904,300 yuan for the first half of 2022, reflecting a significant increase compared to previous periods[51]. - The total comprehensive loss for the first half of 2022 was CNY 36,206,585.58, compared to a loss of CNY 31,570,621.78 in the first half of 2021[122]. - The company reported a net profit of 29,877 million yuan for the first half of 2022, up from 27,572 million yuan in the same period last year, indicating an increase of 8.3%[132]. - The total revenue for the first half of 2022 was 40,646 million yuan, which is a 7.3% increase compared to 37,606 million yuan in the previous year[134]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥7,105,657.94, a 155.37% increase from -¥12,832,855.88 in the same period last year[19]. - Total cash inflow from operating activities decreased to ¥145,792,927.36 in the first half of 2022, down from ¥168,523,613.72 in the first half of 2021, representing a decline of approximately 13.5%[128]. - Cash outflow from operating activities also decreased to ¥138,687,269.42 in the first half of 2022, compared to ¥181,356,469.60 in the first half of 2021, indicating a reduction of about 23.5%[128]. - The ending cash and cash equivalents balance decreased to ¥27,916,083.05 at the end of the first half of 2022, down from ¥39,469,926.67 at the end of the first half of 2021[129]. Assets and Liabilities - Total assets at the end of the reporting period were ¥759,906,697.80, down 4.93% from ¥799,312,074.12 at the end of the previous year[19]. - The total liabilities decreased to CNY 149,336,912.77 from CNY 152,535,703.51, reflecting a reduction of approximately 2%[118]. - The total equity attributable to shareholders decreased to CNY 573,106,412.32 from CNY 606,033,621.98, representing a decline of about 5.4%[118]. - Accounts receivable decreased to ¥91,678,802.4, representing 12.06% of total assets, down from 14.93% last year[41]. - Inventory increased slightly to ¥432,519,973, accounting for 56.92% of total assets, up from 53.88%[41]. Research and Development - Research and development expenses decreased by 27.31% to ¥30,076,280.23 from ¥41,376,753.42 year-on-year[36]. - The company has five invention patents and three new drug certificates, indicating a strong focus on innovation in the biopharmaceutical sector[34]. - The company has allocated 3,600 million yuan for research and development in the current fiscal year, which is a 10% increase from the previous year[134]. Business Operations - The main business includes the production and sales of biopharmaceutical products, focusing on treatments for cancer and anemia[26]. - The company operates an independent and complete procurement, production, and sales model, continuously improving its business model based on market demand[26]. - The sales model primarily relies on distributors to sell products to hospitals, while the company manages product development and academic promotion internally[32]. - The company has established a qualified supplier database to ensure the procurement of raw materials meets production needs[30]. Market and Strategic Initiatives - The company plans to expand its market presence and invest in new product development to drive future growth[134]. - The company aims to enhance its operational efficiency through strategic mergers and acquisitions in the upcoming quarters[134]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[135]. Corporate Governance and Compliance - The company has established a relatively complete corporate governance structure, ensuring equal rights for all shareholders, especially minority shareholders[71]. - The company actively explores and improves corporate governance in accordance with relevant laws and regulations[71]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring compliance and transparency in financial reporting[147]. Environmental and Social Responsibility - The company is committed to reducing carbon emissions and has developed emergency response plans for environmental incidents, demonstrating its focus on sustainability[65]. - The company has received approval for its wastewater discharge permit, ensuring compliance with environmental regulations and enhancing its environmental management capabilities[64]. Risks and Challenges - The company is facing risks related to the COVID-19 pandemic, which may impact production operations and increase costs for raw materials, labor, and logistics[52]. - The company is actively managing litigation risks related to a securities false statement lawsuit, with ongoing efforts to respond and disclose updates[55].